Cancer Imaging with Radiolabeled Antibodies

I. Historical and Theoretical Perspectives.- 1. Clinical radioimmunodetection: The second decade.- 2. Antibody targeting: Theoretical considerations.- II. Model Systems.- 3. Experimental model systems for antibody targeting and radioimmunodetection.- 4. Preclinical models and methods for the study of radiolabeled monoclonal antibodies in cancer diagnosis and therapy.- 5. Physiology of monoclonal antibody accretion by tumors.- 6. Intraperitoneal delivery of monoclonal antibodies.- III. Radiochemistry.- 7. Chelates and antibodies: Current methods and new directions.- 8. Radiolabeling antibodies via the cyclic anhydride of DTPA — Experiences of 5 years.- 9. Bifunctional chelating agents for radiometal-labeled monoclonal antibodies.- 10. Optimization of biodistribution by introducing different chemical linkages between antibody and an indium-111 chelate.- 11. Novel bifunctional linkers for antibody chelation with radiometals.- 12. Labeling of anti-tumor antibodies and antibody fragments with Tc-9m.- IV. Clinical Studies.- 13. Requirements for the use of radioimmunodetection of cancer in clinical practice.- 14. In-vivo antibody imaging for the detection of human tumors.- 15. In-111 monoclonal antibody immunoscintigraphy of colorectal cancer.- 16. Tumor targeting with monoclonal antibody B72.3: Experimental and clinical results.- 17. Antibody imaging of endocrine tumors.- 18. Diversity of the human immune response to clinically used murine monoclonal antibodies.- V. New Approaches.- 19. Antibody lymphoscintigraphy.- 20. Radioimmunoguided surgery: A new intraoperative approach to the detection of tumor.- 21. Augmentation of tumor antigen expression by recombinant human interferons: Enhanced targeting of monoclonal antibodies to carcinomas.- 22. Anti-antibody enhancement oftumor imaging.